Calcium carbonate/melatonin/pyridoxine Disease Interactions
There are 9 disease interactions with calcium carbonate / melatonin / pyridoxine.
- Depression
- Phosphate calcifications
- Cardiac contraction/conduction
- Malabsorption
- Renal dysfunction
- Sarcoidosis
- Glaucoma
- Liver disease
- Malabsorption
Anxiolytics/sedatives/hypnotics (applies to calcium carbonate/melatonin/pyridoxine) depression
Major Potential Hazard, Moderate plausibility.
A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.
References (14)
- (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
- (2001) "Product Information. Ambien (zolpidem)." sanofi-aventis
- (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
- (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
- (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
- (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical
- (2002) "Product Information. Xyrem (sodium oxybate)." Orphan Medical
- (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
- (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
- (2010) "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals
- (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
- (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
- (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
Calcium salts (applies to calcium carbonate/melatonin/pyridoxine) calcium- phosphate calcifications
Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance
Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. These complexes are eliminated in the feces. Clinical monitoring of serum calcium and phosphate concentrations is necessary.
References (2)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
Calcium salts (applies to calcium carbonate/melatonin/pyridoxine) cardiac contraction/conduction
Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias
Calcium is involved in cardiac muscle contraction and electrical impulse conduction. Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease. Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias. Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.
References (2)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
Calcium salts (applies to calcium carbonate/melatonin/pyridoxine) malabsorption
Major Potential Hazard, High plausibility. Applicable conditions: Achlorhydria, Malabsorption Syndrome
Calcium is absorbed from the intestinal tract by active transport and passive diffusion. Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium. Calcium is available in oral and parenteral formulations.
References (2)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
Calcium salts (applies to calcium carbonate/melatonin/pyridoxine) renal dysfunction
Major Potential Hazard, High plausibility.
Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment. Hyperphosphatemia occurs during renal failure. Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure. Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.
References (2)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
Calcium salts (applies to calcium carbonate/melatonin/pyridoxine) sarcoidosis
Major Potential Hazard, High plausibility.
Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis. Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma. Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.
References (3)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
- Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD (1998) "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division
Anxiolytics/sedatives/hypnotics (applies to calcium carbonate/melatonin/pyridoxine) glaucoma
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Urinary Retention
Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.
References (2)
- (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
- (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
Anxiolytics/sedatives/hypnotics (applies to calcium carbonate/melatonin/pyridoxine) liver disease
Moderate Potential Hazard, Moderate plausibility.
In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.
References (13)
- (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
- (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
- (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
- (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
- (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical
- (2002) "Product Information. Xyrem (sodium oxybate)." Orphan Medical
- (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
- (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
- (2010) "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals
- (2011) "Product Information. Intermezzo (zolpidem)." Purdue Pharma LP
- (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
- (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
Vitamin B complex (applies to calcium carbonate/melatonin/pyridoxine) malabsorption
Moderate Potential Hazard, High plausibility. Applicable conditions: Alcoholism, Malabsorption Syndrome, Cirrhosis
The B vitamins are readily absorbed in the GI tract following oral administration. However, GI absorption may be decreased in patients with malabsorption syndromes and other conditions. For example, the absorption of thiamine and pyridoxine may commonly be decreased in alcoholics and in patients with cirrhosis. Likewise, riboflavin absorption may be impaired in patients with hepatitis, cirrhosis, or biliary obstruction. When malabsorption of these vitamins is suspected, parenteral administration may be appropriate.
References (3)
- "Product Information. Vitelle Nestrex (pyridoxine)." Fielding Company
- (2001) "Product Information. Vitamin B1 (thiamine)." Dixon-Shane Inc
- "Product Information. Quinine (riboflavin)." Watson/Rugby Laboratories Inc, Norcross, GA.
Calcium carbonate/melatonin/pyridoxine drug interactions
There are 517 drug interactions with calcium carbonate / melatonin / pyridoxine.
Calcium carbonate/melatonin/pyridoxine alcohol/food interactions
There are 2 alcohol/food interactions with calcium carbonate / melatonin / pyridoxine.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.